Eslicarbazepine for focal epilepsy and acute intermittent porphyria

Epileptic Disord. 2020 Jun 1;22(3):349-352. doi: 10.1684/epd.2020.1171.

Abstract

Porphyrias are rare genetic disorders which cause a deficiency in the enzymes involved in the biosynthesis of heme. The treatment of epilepsy in patients with acute intermittent porphyria can be difficult since many anticonvulsants can increase heme synthesis and trigger porphyric attacks. We report a patient with focal epilepsy successfully treated with eslicarbazepine without exacerbation of porphyria.

Keywords: carbamazepine; eslicarbazepine; hepatic porphyria.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticonvulsants / administration & dosage
  • Anticonvulsants / pharmacology*
  • Comorbidity
  • Dibenzazepines / administration & dosage
  • Dibenzazepines / pharmacology*
  • Epilepsies, Partial / drug therapy*
  • Epilepsies, Partial / epidemiology
  • Female
  • Humans
  • Porphyria, Acute Intermittent* / epidemiology

Substances

  • Anticonvulsants
  • Dibenzazepines
  • eslicarbazepine